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 There has been little research into the socioeco-
nomic burden associated with non-alcoholic stea-
tohepatitis (NASH).
 Direct medical, direct non-medical and indirect
costs resulting from NASH were captured in a real-
world setting.
 Extrapolating the per-patient cost to a population
level demonstrates the rising prevalence of NASH
and related comorbidities.https://doi.org/10.1016/j.jhepr.2020.100142There has been little research into the socioeconomic
burden associated with non-alcoholic steatohepatitis
(NASH). The GAIN study provides real-world data on
the direct medical, direct non-medical, and indirect
costs associated with NASH, including patient-
reported outcomes in five European countries (UK,
France, Germany, Spain, and Italy) and the USA. Mean
total annual per patient cost of NASH was estimated at
V2,763, V4,917, and V5,509 for the direct medical,
direct non-medical, and indirect cost categories,
respectively.
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Background & Aims: Non-alcoholic steatohepatitis (NASH) leads to cirrhosis and is associated with a substantial socioeco-
nomic burden, which, coupled with rising prevalence, is a growing public health challenge. However, there are few real-world
data available describing the impact of NASH.
Methods: The Global Assessment of the Impact of NASH (GAIN) study is a prevalence-based burden of illness study across
Europe (France, Germany, Italy, Spain, and the UK) and the USA. Physicians provided demographic, clinical, and economic
patient information via an online survey. In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis
score and by biomarkers as either early or advanced fibrosis. Per-patient costs were estimated using national unit price data
and extrapolated to the population level to calculate the economic burden. Of the patients, 767 (20%) provided information on
indirect costs and health-related quality of life using the EuroQOL 5-D (EQ-5D; n = 749) and Chronic Liver Disease Ques-
tionnaire – Non-Alcoholic Fatty Liver Disease (CLDQ-NAFLD) (n = 723).
Results: Mean EQ-5D and CLDQ-NAFLD index scores were 0.75 and 4.9, respectively. For 2018, the mean total annual per
patient cost of NASH was V2,763, V4,917, and V5,509 for direct medical, direct non-medical, and indirect costs, respectively.
National per-patient cost was highest in the USA and lowest in France. Costs increased with fibrosis and decompensation,
driven by hospitalisation and comorbidities. Indirect costs were driven by work loss.
Conclusions: The GAIN study provides real-world data on the direct medical, direct non-medical, and indirect costs asso-
ciated with NASH, including patient-reported outcomes in Europe and the USA, showing a substantial burden on health
services and individuals.
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Non-alcoholic fatty liver disease (NAFLD) includes a spectrum of
liver disease defined by an excessive accumulation of fat (tri-
glycerides) in hepatocytes, ranging from hepatic steatosis (non-
alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis
(NASH), liver cirrhosis, and hepatocellular carcinoma. NAFLD
does not result from alcohol consumption but rather is associ-
ated with obesity, insulin-resistance/type 2 diabetes mellitus
(T2DM), hypertension, and dyslipidaemia.1,2 NAFLD is one of the
most common causes of chronic liver disease worldwide,3 esti-
mated to affect 25% of the adult population globally,4 includingKeywords: Non-alcoholic steatohepatitis; Cost of illness; Cross-sectional studies;
Europe.
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population, NASH (the more progressive form of the disease) has
a reported prevalence of 5–20%,7 but may occur more frequently
in people who are obese or diabetic.8 Considering the global rise
of obesity and the ageing population, NASH is a serious public
health challenge that is predicted to become increasingly
prevalent.4,9
NASH is distinguished from NAFLD histologically by the
presence not only of steatosis, but also of inflammation and
hepatocyte ballooning, with or without fibrosis.10 Therefore, liver
biopsy remains the current standard for NASH diagnosis.11
However, this procedure is associated with complications and,
thus, is limited by patient acceptability as well as by cost and
sampling error.11 In that context, guidelines recommend the
initial use of blood-based simple scores12 or biomarkers, such as
Fibrosis-4 (FIB-4) or enhanced liver fibrosis scores and imaging
techniques (e.g. transient elastography) to triage patients based
on the likelihood of NASH being present with more advanced
stages of fibrosis.13,14
Research articleNASH-associated mortality increases exponentially with
fibrosis stage.8 However, there is substantial interpatient varia-
tion in disease progression and outcomes. Although under-
standing of the factors that affect interpatient variation in
disease outcome remains incomplete, NAFLD is best considered a
complex disease trait where environmental factors act upon a
genetically and epigenetically determined background to modify
natural history and outcome.15 In long-term follow-up studies,
40% of patients exhibited progressive disease, 40% stable dis-
ease, and 20% disease regression during follow-up.16,17 Initially,
cirrhosis is not clinically apparent, and is termed ‘compensated
cirrhosis’; however, emerging data suggested that health-related
quality of life (HRQoL) is impaired during earlier stages of
NASH.18 Over time, individuals experience hepatic decompen-
sation, characterised by jaundice, ascites, variceal haemorrhage,
and encephalopathy.19
The current standard of care for NASH management com-
prises lifestyle changes (i.e. diet and exercise) and medication for
comorbidities, such as diabetes and hypertension.13 Individuals
with early NAFLD are generally managed in primary care, with
lifestyle modification. By contrast, patients with NASH and more
advanced fibrosis require a multidisciplinary approach, and are
currently optimally managed in a secondary-care setting.13 There
is currently no pharmacological treatment licenced for NASH,
although clinical guidelines recommend that specific antidia-
betic and antioxidant drugs (e.g. pioglitazone and vitamin E) can
be used in selected patients with fibrosing-steatohepatitis.13
Bariatric surgery induces weight loss and, thus, may also
improve fibrosis.13 To date, the only curative treatment for
cirrhosis is liver transplantation. In the USA, NASH cirrhosis-
related liver transplantations increased from 1.2% in 2001 to
9.7% in 2009,20 and NASH is expected to become the leading
need for liver transplantation in the near future.10,21,22
A recent study developed a steady-state prevalence model to
estimate the economic burden of NAFLD. This suggested that
more than 64 million people in the USA and around 52 million
people in France, Germany, Italy and the UK have NAFLD.23 The
annual direct medical costs associated with NAFLD were esti-
mated to be US$103 billion/V89 billion (US$1,613/V1,430 per
patient) in the USA and V35 billion (from V354 to V1,163 per
patient) in Europe. Total costs were highest in patients aged
between 45 and 65 years, and the burden was predicted to be
significantly higher when societal costs were included, although
these were not quantified.23
The overall aim of the Global Assessment of the Impact of
NASH (GAIN) study was to determine the real-world humanistic
and socioeconomic burden of NASH in adult patients in Europe
and the USA. The primary objective was to explore the impact of
NASH on patients’ HRQoL using patient-reported outcome
measures. The secondary objective was to estimate the total
annualised cost of the disease, including all health-related items
and non-health and indirect costs accrued by patients and their
families. Patient stratification by country and fibrosis stage added
granularity to the analyses.Patients and methods
Study design
GAIN was a retrospective, cross-sectional study involving phy-
sicians and patients providing past and present clinical and
economic data from five European (EU5) countries (France,
Germany, Italy, Spain, and the UK) and the USA. Patients eligibleJHEP Reports 2020for inclusion in the study were adults (18 years and over) found
to have NASH, following exclusion of other potential liver dis-
eases, confirmed at least 12 months before the date at which
they were recruited. Although a definitive NASH diagnosis re-
quires confirmation from liver biopsy, some patients either are
unwilling to undergo a biopsy or have a contraindication to it.
Restricting recruitment to only patients with a biopsy-confirmed
NASH diagnosis would have biased the cohort towards patients
under tertiary care and, thus, be unrepresentative of most real-
world patients with NASH, who are managed in the primary
and/or secondary-care setting. To address this, the expert
Steering Committee (membership details are included in the
supplemental information online) recommended that the diag-
nostic criteria for NASH be broadened to include: (i) histologi-
cally confirmed NASH with fibrosis; (ii) clinical biochemistry
and/or serum biomarkers indicating advanced fibrosis (e.g. AST/
ALT ratio, NAFLD fibrosis score, BARD score [derived from AST/
ALT ratio, body mass index, and presence of diabetes], and FIB-4
score) in patients with metabolic syndrome risk factors; or (iii)
imaging techniques (ultrasound or MRI elastography, or CT im-
aging) indicating advanced fibrosis and/or cirrhosis in patients
with metabolic syndrome risk factors. These latter non-invasive
diagnostic procedures are able to reliably discriminate between
advanced fibrosis (F3–F4) and early-stage fibrosis (F0–F2),24 but
do not reliably differentiate intermediate stages of fibrosis.
Specialists provided information on direct medical resource
utilisation and clinical and demographic data based on recorded
notes data using a web-based case record form (CRF). They
recruited eligible patients consecutively as they attended a
clinical appointment, regardless of the reason for their consul-
tation. Additionally, several patients completed (on a voluntary
basis) a survey called the Patient Public Involvement Engage-
ment (PPIE) questionnaire following the consultation, providing
information about indirect and direct non-medical resource use.
patient-reported outcome measures were assessed using vali-
dated instruments. Generic HRQoL was evaluated using EuroQol
EQ-5D-5L.25 Disease-specific HRQoL was evaluated with the
Chronic Liver Disease Questionnaire (CLDQ)-NAFLD; this reports
on six domains: abdominal symptoms, activity, emotions, fa-
tigue, systemic symptoms, and worry.18
Through the above-mentioned CRFs, physicians collected
relevant clinical and economic retrospective data at the time of
patient consultation, which occurred between June and October
2018. Estimates of healthcare utilisation and costs were then
calculated for the 12-month period. The online format of the
CRFs ensured that numeric responses were kept within reason-
able boundaries, and that infeasible responses (such as the
ability to provide twomutually exclusive responses) were kept to
a minimum. Nevertheless, a small amount of post-hoc data pro-
cessing was conducted based on expert clinical guidance.
All patient participants provided written informed consent.
The study protocol was approved by the Research Ethics Sub-
committee of the Faculty of Health and Social Care within the
University of Chester. The approval stipulated that the study was
to be carried out in correspondence with regional and relevant
guidelines, and the 1975 Declaration of Helsinki. For further
details regarding the materials used, please refer to the CTAT
table and supplementary information.
Cost estimation
Direct medical and non-medical costs were sourced from official
country-specific data bases, as well as other non-country-specific2vol. 2 j 100142
where P = price, Q = resource use, and i = 1 − n (where
Table 1. Study population and basic demographics.
Demographic
NASH disease stage
OverallEarly (F0–F2) Advanced (F3–F4)
No. of patients 2,604 (69) 1,150 (31) 3,754 (100)
Male 1,493 (57) 657 (57) 2,150 (57)
Female 1,111 (43) 493 (43) 1,604 (43)
Age (n) 2,604 1,150 3,754
Mean (SD) 52 (12.0) 55 (11.4) 53 (11.9)
Body mass index (n)a 2,604 1,104 3,754
Mean (SD) 30.8 (9.0) 30.7 (7.8) 30.8 (8.7)
Country (n) 2,604 1,150 3,754
Germany 364 (67) 176 (33) 540 (100)
Spain 363 (70) 159 (30) 522 (100)
France 346 (68) 162 (32) 508 (100)
UK 322 (76) 101 (24) 423 (100)
Italy 377 (70) 163 (30) 540 (100)
USA 832 (68) 389 (32) 1,221 (100)
Data are presented as n (%), unless otherwise indicated.
a Calculated on a post hoc basis using information from patients’ height and weight.sources, grey literature, and publicly available data (including
commercial databases for non-medical costs and international
websites, such as the World Health Organization and the Orga-
nisation for Economic Co-operation and Development data-
bases). For instance, in the USA, the main sources of data were
the Medicaid National Average Drug Acquisition Cost database
for drug costs, the Centre for Medicare and Medicaid services for
test procedures and surgeries, and the American Medical Asso-
ciation for consultations. For a list of all the used sources, refer to
Table S1 in the supplemental information online. The choice of
resources to be included in the GAIN study was defined by so-
cietal perspective. Cost categories included both NASH-related
and non-NASH-related events. The total cost burden was cat-
egorised broadly as either direct or indirect expenditures. Direct
medical costs included not only medication, hospitalisations,
consultations, and surgical interventions, but also all tests and
procedures used for diagnosis and follow-up of the disease.
Direct non-medical costs included elements of professional and
informal caregiving, alternative therapies, aids and home
equipment/adaptations, and transportation and transfer pay-
ments (including state benefits or disability allowances). Over-
the-counter (OTC) remedies were included in non-medical
costs for practical reasons: not only were they only reported by
the patient sample via the PPIE questionnaire (as opposed to all
the above-mentioned medical items reported by physicians), but
also most reported elements were dietary supplements, the
medical therapy nature of which can be disputed. Finally, indi-
rect costs were those that were less tangible in relation to the
disease of interest but were nonetheless quantifiable. These
included the loss of wages and productivity because of absen-
teeism or impairment while at work. We included loss of wages
by patients, using the country-specific average salaries as a proxy
for the opportunity costs.
Direct medical cost variables were obtained from the
physician-reported CRF for all patients. Twenty percent of pa-
tients provided information about direct non-medical costs and
indirect costs. All patients were categorised as having early (F0–
F2) or advanced (F3–F4) fibrosis stage. Additionally, patients
were classified by country to investigate possible differences in
clinical and economic variables. Patients with a biopsy-
confirmed diagnosis were included in the analysis, as well as
patients with a NASH diagnosis using non-invasive diagnostic
tools, such as ultrasound-based transient elastography. The use
of these non-invasive tests that do not accurately differentiate
intermediate stages of fibrosis imply a level of subjectivity in the
physicians’ evaluations and, therefore, the possibility of some
misdiagnoses of NAFLD and NASH.
All local currency total costs were converted to Euros using
the official conversion rate (1 US$ = V0.906756, 1 GB£ = V1.11799
as of September 12, 2019). Per-patient costs were calculated by
multiplying the quantities of the resource used with the national
unit price of each resource (updated to 2018 prices using infla-
tion indicators via http://ec.europa.eu/eurostat/web/hicp/data/
database). To extrapolate the sample costs to country popula-
tion level, the per-patient costs were multiplied by national
prevalence weights26:
Pi ×Q i ¼ Costi
Costi ×prevalence weights from the literature ¼ population cost;JHEP Reports 2020n = number of cost items).
Results
CRFs were completed by 337 physicians, who recruited data from
3,754 patients. Among these, 1,619 patients (43%) had a histo-
logical diagnosis of NASH, staged by locally reported liver biopsy.
Of the total patients, 767 (20%) completed a PPIE, which was
matched to the corresponding CRF. Patient response rates ranged
from 5% in the UK to 41% in Italy (Table S1 in the supplemental
information online).
The main characteristics of the patients are summarised in
Table 1. The demographics showed a slight preponderance
of males, mean age in the low 50s (but higher in individuals
with more advanced fibrosis) and a high level of obesity
(BMI >30).NAFL/NASH diagnosis and fibrosis scores
The pattern of use of NASH diagnostic tests was consistent
across EU5 countries, although did differ from practice in
the USA. Routine clinical tests, including liver biochemistry,
were commonly performed. Overall, ultrasound imaging
was the most frequently used diagnostic technique, with
2,550 (68%) patients undergoing an ultrasound. Serum
biomarkers and non-invasive tests to risk-stratify NAFLD/
NASH were less commonly applied, despite being advocated
in the European Association for the Study of the Liver,
European Association for the Study of Diabetes, and Euro-
pean Association for the Study of Obesity and American
Association for the Study of Liver Diseases clinical guide-
lines. The most frequently used was AST/ALT ratio (23%),
followed by NAFLD fibrosis score (9%), BARD score (3%), and
the FIB-4 score (3%). Use of the cytokeratin-18 biomarker,
an unvalidated diagnostic tool that detects apoptosis, was
reported in 3% of patients. Transient elastography (Fibro-
scanTM) was the most frequently used imaging test to stage
disease in 1,228 (33%) patients.3vol. 2 j 100142
Table 2. EQ-5D index by country and fibrosis stagea.
Country
NASH disease stage
OverallEarly (F0–F2) Advanced (F3–F4)
France, n 93 31 124
Mean (SD) 0.83 (0.15) 0.82 (0.14) 0.83 (0.15)
Germany, n 94 37 131
Mean (SD) 0.81 (0.16) 0.64 (0.26) 0.76 (0.21)
Italy, n 160 54 214
Mean (SD) 0.85 (0.12) 0.5 (0.41) 0.76 (0.28)
Spain, n 119 47 166
Mean (SD) 0.7 (0.3) 0.57 (0.36) 0.66 (0.32)
United States, n 58 36 94
Mean (SD) 0.80 (0.19) 0.67 (0.23) 0.75 (0.22)
All, n 531 218 749
Mean (SD) 0.80 (0.2) 0.62 (0.33) 0.75 (0.26)
EQ-5D, EuroQOL 5-D; NASH, non-alcoholic steatohepatitis.
a UK data (n = 20) were not used for this question because of a low response rate.
Table 3. CLDQ-NAFLD index by country and fibrosis stagea.
Country
NASH disease stage
OverallEarly (F0–F2) Advanced (F3–F4)
France, n 91 28 119
Mean (SD) 5.7 (0.9) 5.7 (0.7) 5.7 (0.8)
Germany, n 94 36 130
Mean (SD) 5.0 (1.1) 4.2 (1) 4.8 (1.1)
Italy, n 152 53 205
Mean (SD) 5.1 (1) 3.7 (1.5) 4.7 (1.3)
Spain, n 116 44 160
Mean (SD) 5.2 (1.2) 4.6 (1.4) 5.1 (1.3)
USA, n 55 36 91
Mean (SD) 4.7 (1.05) 4.0 (1.12) 4.4 (1.12)
All, n 513 210 723
Mean (SD) 5.2 (1.1) 4.4 (1.4) 4.9 (1.2)
CLDQ-NAFLD, Chronic Liver Disease Questionnaire – Non-Alcoholic Fatty Liver Dis-
ease; NASH, non-alcoholic steatohepatitis.
a UK data (n = 20) were not used for this question because of a low response rate.
Research articleKey differences in practice between the EU5 countries and
USA were that imaging techniques were less frequently used in
the USA: 618 (51%) patients received an ultrasound compared
with an average of 76% in EU5 countries; and only a minority
received transient elastography: 157 (13%) compared with a total
of 1,071 (42%) in EU5 countries. CT and MRI are predominantly
indicated during follow-up in more severely affected patients
(e.g. for screening or diagnosing hepatocellular carcinoma) and
had been used in 20% and 18% of the sample, respectively. The
reported rate of liver biopsy was lowest in Spain (130 patients,
25%), and highest in the USA (697, 57%).
One or more comorbidities were reported in 64% of patients,
with a higher prevalence in patients with more advanced dis-
ease. Consistent with the association of NAFLD/NASH with the
metabolic syndrome, the most frequent comorbidities were
obesity (35% of patients), dyslipidaemia (32%), T2DM (27%), and
hypertension (27%). Comorbidity rates showed a relatively
similar trend across countries. Obesity and dyslipidaemia were
most frequent in French (48% and 42%, respectively) and British
(41% and 38%, respectively) patients, whereas Italy had the
lowest rates of both (24% and 27%, respectively). The rate of
hypertension was similar in most countries but slightly higher in
France (38%). Depression was the most common mental and
behavioural disorder, reported by 8% of patients overall and
ranging from 10% in Italy (10%) to 6% in the USA. Cardiovascular
diseases (excluding hypertension) were most commonly re-
ported in Germany (18%), and least commonly reported in the
USA (4%).
HRQoL
The EQ-5D score decreased with fibrosis status (early vs.
advanced) and varied by country (Table 2). In general, there was
a clear pattern of decreasing HRQoL score with worsening
fibrosis score in all countries, with the exception of France,
where similar scores were seen in both early and advanced
fibrosis.
The average CLDQ-NAFLD index was 4.9, with France having
the highest score at 5.7 and the USA having the lowest score of
4.4 (Table 3). There was also a soft trend for CLDQ-NAFLD score
to decrease with fibrosis stage although this was not observed in
all territories.JHEP Reports 2020Direct medical costs
Mean annual NASH-related direct medical costs per patient (see
Table S2 in the supplemental information online for all sub-
categories) were V2,763 (Table 4); the direct costs for NASH and
non-NASH elements (of which >70% were for medication) are
provided in the Tables S3 and S4 in the supplemental informa-
tion online, and the total combined direct costs were V4,754
(Table 4).
Despite the lack of drugs specifically licenced for the treat-
ment of NASH, the main component of NASH-related direct costs
reported by physicians was pharmacological therapy. It is chal-
lenging to determine the exact motivation for prescribing spe-
cific agents in a multisystem disease, such as NASH, that is
frequently associated with other metabolic diseases. However,
separate to use for comorbidities, clinicians reported ‘off-label’
prescribing of a range of medication for presumed additional
direct therapeutic benefit on NASH. These principally included
medication ostensibly targeting obesity (orlistat [5.1% of pa-
tients]) or components of the metabolic syndrome (statins
[18.4%], metformin [15.5%], losartan [4.2%], fenofibrate [4.3%],
and omega-3 fatty acids [5.3%]), with or without evidence of
additional liver-directed therapeutic benefits, and drugs directly
targeting the liver (vitamin E [12.2%], ursodeoxycholic acid
[5.7%], and pentoxifylline [1.1%]). Some agents (e.g. vitamin E)
have clinical trial evidence to support their use and are included
in clinical guidelines, whereas others lack strong evidence of
direct hepatic effects but may have broader therapeutic benefits
on metabolic disease. For example, metformin has been shown
to reduce the development of T2DM27–29; thus, its use in patients
without diabetes but with NASH may have been driven by this
consideration and the evidence that there is a bi-directional
relationship between NASH and T2DM.1 Surgical procedures,
including weight-loss procedures and liver transplantation, were
also reported (Table S3 in the supplemental information online).
Overall, costs for patients with advanced fibrosis were higher
(V3,983) than for those with early-stage fibrosis (V2,224). Again,
pharmacological costs were the highest cost itemwithin the per-
patient non-NASH-related costs, with up to 27 different drugs
prescribed to treat comorbidities, and statins, metformin, and
angiotensin-converting enzyme inhibitors being the most
commonly prescribed drugs (in 21%, 18%, and 8% of all patients,
respectively), likely reflecting the strong metabolic4vol. 2 j 100142
Table 4. Mean annual total (NASH-related and non-related) direct costs by country (SD).
Cost
NASH stage Country
OverallEarly Advanced Germany Spain France UK Italy USA
n 2,604 1,150 540 522 508 423 540 1,221 3,754
NASH-related (A) V2,224
(19,956)
V3,983
(23,788)
V1,917
(7,715)
V2,162
(10,220)
V1,357
(5,427)
V1,851
(2,406)
V1,732
(7,799)
V4,881
(42,077)
V2,763
(21,216)
Non-NASH (B) V1,659
(4,117)
V2,743
(6,107)
V1,712
(3,698)
V1,161
(3,200)
V1,082
(2,234)
V2,027
(2,897)
V1,006
(2,397)
V2,957
(7,170)
V1,991
(4,840)
Total (A+B) V3,883
(20,634)
V6,727
(25,052)
V3,629
(8,795)
V3,323
(11,258)
V2,440
(6,241)
V3,879
(3,811)
V2,739
(8,296)
V7,258
(36,704)
V4,754
(22,117)
NASH, non-alcoholic steatohepatitis.
Table 5. Mean annual non-medical and indirect costs (SD) reported by patients with NASH by country.
Cost
NASH stage Country
OverallEarly Advanced Germany Spain France UK Italy USA
n 546 221 132 169 130 20 219 97 767
Non-medical V1,704
(5,785)
V4,661
(9,839)
V2,695
(7,273)
V4,713
(10,828)
V213
(920)
V2,063
(3,707)
V1,977
(5,515)
V3,243
(7,685)
V2,556
(7,308)
Indirect V5,939
(15,989)
V12,642
(21,813)
V11,624
(24,003)
V9,541
(18,223)
V2,530
(9,137)
V4,994
(8,166)
V5,451
(12,175)
V13,435
(29,493)
V7,871
(18,104)
NASH, non-alcoholic steatohepatitis.comorbidities. These costs were highest in the USA (V2,957) and
lowest in France (V1,006).Non-medical costs and indirect costs
Patients provided information about both direct non-medical
and indirect (productivity) costs. The overall direct non-
medical cost per patient was V4,917 (Table 5). Professional
(34%) and informal (48%) caregivers accounted for most of these
costs and these percentages increased with disease severity
(fibrosis stage). At the country level, there were large differences
in professional and informal caregiver costs among different
countries. This variability may reflect not only cultural differ-
ences, but also the relatively low sample size in each country (see
Table S1 in the supplemental information online, with a range of
5% of returned questionnaires from patients in the UK to 41%
in Italy).
The remaining direct non-medical costs resulted from
transport, disability allowances, alternative therapies, home
alteration, and OTC remedies. Notably, these costs did not
correlate with disease severity, and were evenly distributed
among countries, with the exception of the UK and France,
where costs of these items were proportionally higher. The UK
has the highest cost reported for transportation and for OTC
remedies; however, the sample size was the lowest of all
countries and, thus, these findings should be interpreted with
caution.
Total indirect costs were very high, reaching V5,509 (Table 5)
and clearly correlating with disease severity. There was large
variability between countries (Table 5), with the lowest costs in
France (V2,530) and the highest costs in Germany (V11,624) and
the USA (V13,435).
A major share of indirect costs resulted from early retirement
or stopping working (74%), followed by time off work in the
previous 12 months (26%). Patient indirect or productivity-
related costs correlated positively with NASH severity, because
patients with relatively more severe disease had to stop working
(12% vs. 5% in patients with early-stage disease) or cited thatJHEP Reports 2020their retirement was the result of NASH (13% vs. 5% in patients
with early-stage disease); in addition, more patients with
advanced NASH experienced work-related problems or sick
leaves compared with patients with early-stage disease (74% vs.
53%, respectively).Extrapolation of NASH medical costs to a national burden
The average NASH-related costs were V2,763, V4,917, and
V5,509 per patient for direct medical, direct non-medical, and
indirect cost categories, respectively. Adding the non-NASH-
related costs borne by the patient increased the average total
direct medical cost to V4,754 (Table 4).
The size and representativeness of the GAIN study CRF sample
data was used to extrapolate the total medical cost of NASH using
model-based prevalence estimations for the six countries from
Estes et al.,4 where a further adjustment was performed to ac-
count for the different proportion or weights of fibrosis stages
observed in clinical practice. The mean costs for patients with
early or advanced-stage NASH in each country in the GAIN study
were weighted by the respective proportions of patients with
early or advanced-stage NASH following estimations from the
aforementioned study (using information from their Table 1 and
Fig. 24).
For example, in France, the adjusted prevalence of NASH was
2.3 million and the total per-patient NASH cost was V848 and
V2,445 for patients with early or advanced-stage NASH,
respectively, which, coupled with the prevalence estimations for
a population with early or advanced-stage NASH would give a
population cost of close to V2.6 billion annually. The adjusted
NASH prevalence was much higher than in the USA than in
France. Also, in the USA, 17 million people were estimated to
have NASH and, therefore, the total expenditure on NASH was
almost V80 billion annually. The national medical costs for pa-
tients with NASH are expected to be even higher if resource use
related to treatment of concomitant conditions is added,
including pharmacological treatment, consultations, and
hospitalisations.5vol. 2 j 100142
Table 6. Total economic burden of NASH by country, using only medical NASH costs (SD).
Characteristic
Country
Germany Spain France UK Italy USA
Country population (4) 80,700,000 46,100,000 64,700,000 64,200,000 59,800,000 324,100,000
NASH prevalence, % (4) 4.10 3.90 3.60 4.10 4.40 5.30
Total NASH cases 3,308,700 1,797,900 2,329,200 2,632,200 2,631,200 17,177,300
CRF sample, n 540 522 508 423 540 1,221
Direct NASH medical costs V1,917 (7,715) V2,162 (10,220) V1,357 (5,427) V1,850 (2,406) V1,732 (7,799) V4,880 (42,077)
NASH drug costs, Tx only V655 (2,218) V739 (3,047) V502 (1,292) V624 (1,733) V431 (1,718) V2,240 (6,116)
Costs, early-stage fibrosis V909 (3,426) V1,311 (3,001) V848 (1,582) V1,638 (2,072) V1,189 (5,110) V4,466 (34,876)
Early-stage NASH cases (4) 2,680,047 1,402,362 1,968,174 2,079,438 2,052,336 13,702,124
Costs, advanced-stage fibrosis V4.002 (12,349) V4,107 (17,840) V2,445 (9,253) V2,655 (3,139) V2,989 (11,811) V5,326 (37,112)
Advanced-stage NASH cases (4) 628,653 395,538 361,026 552,762 578,864 3,475,176
National medical costs of NASH V4,952,604,679 V3,462,650,582 V2,551,899,368 V4,873,746,196 V4,170,141,834 V79,701,054,554
Conservative prevalence scenario of 1.50% NASH cases per country (5)
NASH prevalence (5) 1.50% 1.50% 1.50% 1.50% 1.50% 1.50%
Total NASH cases 1,210,500 691,500 970,500 963,000 897,000 4,861,500
National medical costs of NASH V1,811,928,541 V1,331,788,686 V1,063,291,403 V1,783,077,877 V1,421,639,262 V22,556,902,232
CRF, case record form; NASH, non-alcoholic steatohepatitis; Tx, treatment.
Research articleHowever, the population costs rely on an estimated preva-
lence that is assumed to be accurate and a close representation of
the real prevalence of NASH in the countries included in this
study. For example, in the paper by Younossi et al.,5 the preva-
lence of NASH ranged between 1.5% and 6.45% globally, which
would provide similar cost projections for their mean point
estimation (3.98%, in line with those from Table 6 and from the
study by Estes et al.4). If we used the lower bounds of the
prevalence figures from Younossi et al.5 (1.5%), the total costs
projections would decrease proportionally, with total annual
NASH costs ranging between V1 billion in France and V22.5
billion in the USA. These figures might be subject to change
when new prevalence studies are published.Discussion
The GAIN study aimed to provide comprehensive and accurate
insight into the cost landscape for the real-world NASH popu-
lation across the EU5 countries and the USA, and, to our
knowledge, it is the first research of its kind to adopt a societal
perspective.
Direct medical costs for non-NASH related events were
almost as high as medical costs for NASH-related events for each
of the countries. With the exception of France, direct non-
medical and indirect costs for each country were high. This is
consistent with the finding reported by Younossi et al.23 in their
cost of illness study, where calculated societal costs were
consistently higher than medical costs (despite the differences in
methodology between the two studies). There is currently a
remarkably paucity of data focussing on the costs of patients
with NAFLD and NASH (whether including or excluding costs
unrelated to NASH); nevertheless, Younossi et al.23 reported a
NAFLD per-patient cost of V1,463 in the USA and in the range of
V354–V1,163 in four EU countries (Germany, France, Italy, and
the UK). These costs would lead to a total country cost of V93.4
billion in the USA and V35 billion for the four countries in
Europe in the population with NAFLD. The costs predicted by
GAIN for NASH only (excluding cost for concomitant conditions)
were almost V80 billion in USA and V20 billion in the EU5
countries.
The only known literature review on the topic is that by
Younossi and Henry,30 where 600 citations were reviewed butJHEP Reports 2020only six studies retrieved for detailed evaluation. However, only
one of the six studies, performed by Ghamar Chehreh et al.31 in
the Iranian population, used a similar methodology (i.e. cross-
sectional study estimation of NAFLD cost per patient per year)
with an annual average equivalent cost of US$5,043 per patient.
Nevertheless, the comparability between these studies and the
GAIN study must be interpreted with caution for several reasons,
not only because NAFLD and NASH are different populations, but
also because of the use of different methodologies for collecting
resource use data and the use of different prevalence estimations
in each country.
Caregivers, whether professional or informal, accounted for
the greatest proportion of direct non-medical costs. Further-
more, indirect per patient costs were higher than medical direct
costs in all countries.
The study also revealed differences in diagnostic practice
between Europe and the USA. The use of ultrasound and other
non-invasive techniques and serum biomarkers was more
frequent in the EU5 countries, whereas, in the USA, propor-
tionately more patients had their diagnosis confirmed by biopsy.
More advanced fibrosis was associated with higher levels of
comorbidity and lower generic and disease-specific QoL scores.
Costs also increased with increasing NASH severity.
Limitations
The patient PPIE sample was self-selected and, therefore, may
not accurately represent the NASH population as a whole. Even
though questions were framed in relation to NASH-specific
burden (e.g. the productivity losses question was “Have you
missed work because of NASH problems in the last 3 months?”),
some physicians and patients might account for other conditions
when responding to these questions and, thus, the possibility of
double counting costs cannot be completely ruled out. Never-
theless, an effort was made to include non-NASH-specific ele-
ments separately in the CRF questionnaires (drugs, consultations,
and hospitalisations exclusively for concomitant conditions).
However, and despite having clearly separated questions for
drugs prescribed for NASH and other comorbidities, it is difficult,
as previously stated, to determine the exact motivation for pre-
scribing specific agents in a multisystem disease, such as NAFLD/
NASH, that is frequently associated with other metabolic dis-
eases. Additionally, some of the subgroups analysed were small,6vol. 2 j 100142
particularly in the patient sample. No quota was enforced for
PPIE questionnaires. As a result, there was a smaller number of
patients reporting EQ-5D at both the earliest and most advanced
fibrosis stage (F0, n = 35 and F4, n = 48). Therefore, the gener-
alisation of these findings to individual countries requires
caution; for example, no patients with F0 NASH in the UK and
France provided HRQoL data from either EQ-5D or CLDQ-NAFLD.
The possibility of recall bias for physicians is minimum, given
that they looked at their patients records to provide CRF data.
This might happen for patients, although the number of ques-
tions where recalling data was needed was kept to a minimum.
A possible limitation was the inclusion of misdiagnosed
(i.e. incorrect distinction between NAFL and NASH) and mis-
classified NASH cases because of the use of non-invasive testing
to diagnose disease. However, the aim of the GAIN study was to
provide a broad picture of the current clinical practice and,
therefore, including only patients with biopsy-confirmed disease
would have focussed the data on a potentially unrepresentative
cohort of patients in secondary and/or tertiary care, which would
have missed the complexity and diversity of this condition. In
fact, the GAIN study revealed that >50% of the overall populationJHEP Reports 2020identified as NASH never underwent a biopsy to confirm their
disease.
There is a scarcity of both QoL and costs (burden of illness)
studies in the NASH field, as well as a wide variability of prev-
alence estimates within the general population. Nevertheless,
given the current global rise in obesity and population ageing,
NASH is considered to be a serious threat to public health and the
associated burden is expected to increase over time. However,
differences in population, and the methodology for collecting
and computing cost and prevalence estimations, make it difficult
to directly compare the results of GAIN and the study by You-
nossi et al.7
In conclusion, the GAIN study has successfully furthered our
understanding of the cost of NASH in the EU5 countries and the
USA, and how these costs differ among the participating coun-
tries. However, there is scope to delve deeper into the study data
set to learn and understand more about the global economic
burden of NASH. For example, further analysis would help
stakeholders understand the drivers of cost and outcomes
among this population, and better understand the causality of
poorer outcomes and higher patient costs.Abbreviations
CLDQ, Chronic Liver Disease Questionnaire; CLDQ-NAFLD, Chronic Liver
Disease Questionnaire – Non-Alcoholic Fatty Liver Disease; CRF, case re-
cord form; EU5, five European; FIB-4, Fibrosis-4; GAIN, Global Assessment
of the Impact of NASH; HRQoL, health-related quality of life; NAFL, non-
alcoholic fatty liver; NAFLD, non-alcoholic fatty liver disease; NASH, non-
alcoholic steatohepatitis; OTC, over-the-counter; PPIE, Patient Public
Involvement Engagement; T2DM, type 2 diabetes mellitus.
Financial support
This study was supported by Novo Nordisk and Gilead Sciences, Europe
Ltd.
Conflict of interest
The authors declare no conflicts of interest that pertain to this work.
Please refer to the accompanying ICMJE disclosure forms for further
details.
Authors’ contributions
JO’H contributed to the study design and governance. AF was principal
investigator, responsible for monitoring the progress of data collection
and contributing to manuscript write-up. HD, LR-C, and BF were
responsible for write-up and ongoing critical review of the article. GP and
GM contributed to statistical analysis of the data and manuscript review.
VH provided feedback for manuscript revision. BJ, MM, TR, IVT, VR, MR-G,
EB, JMS, and QMA were responsible for ongoing study review and feed-
back regarding design, data collection, analysis, and critical review of the
manuscript.Acknowledgements
The draft paper was formatted for publication by Steve Chaplin, Medical
Writer, HCD Economics. The data sets generated and/or analysed during
the current study are held under license by the University of Chester and
are not publicly available, but are available from the corresponding
author on reasonable request.Supplementary data
Supplementary data to this article can be found online at https://doi.org/1
0.1016/j.jhepr.2020.100142.References
Author names in bold designate shared co-first authorship
[1] Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus,
cardiovascular disease or cirrhosis. Nat Rev Gastroenterol 2013;10:330–
344.
[2] Sanyal AJ. NASH: a global health problem. Hepatol Res 2011;41:670–674.
[3] Weiß J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology,
clinical course, investigation, and treatment. Dtsch Arztebl Int
2014;111:447–452.
[4] Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J,
et al. Modeling NAFLD disease burden in China, France, Germany, Italy,
Japan, Spain, United Kingdom, and United States for the period 2016-
2030. J Hepatol 2018;69:896–904.
[5] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global
epidemiology of nonalcoholic fatty liver disease—meta-analytic assess-
ment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.
[6] Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-
alcoholic fatty liver disease. Dig Dis 2010;28:155–161.
[7] Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al.
Global burden of NAFLD and NASH: trends, predictions, risk factors and
prevention. Nat Rev Gastroenterol 2018;15:11–20.
[8] Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk
of mortality by fibrosis stage in nonalcoholic fatty liver disease: system-
atic review and meta-analysis. Hepatology 2017;65:1557–1565.
[9] Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical
epidemiology and disease burden of nonalcoholic fatty liver disease.
World J Gastroenterol 2017;23:8263–8276.
[10] Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a
practical approach to diagnosis and staging. Frontline Gastroenterol
2014;5:211–218.
[11] Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk
factors. World J Gastroenterol 1999;5:301–304.
[12] Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M,
Bodemar G, et al. Long-term follow-up of patients with NAFLD and
elevated liver enzymes. Hepatology 2006;44:865–873.
[13] National Institute for Health and Care Excellence. Non-Alcoholic Fatty
Liver Disease (NAFLD): Assessment and Management. NICE Clinical
Guideline NG49. London: NICE; 2016.
[14] Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver
fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol
2012;8:661–668.
[15] Anstee QM, Seth D, Day CP. Genetic factors that affect risk of alcoholic and
nonalcoholic fatty liver disease. Gastroenterology 2016;150:1728–1744.7vol. 2 j 100142
Research article[16] McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evi-
dence of NAFLD progression from steatosis to fibrosing-steatohepatitis
using paired biopsies: implications for prognosis and clinical manage-
ment. J Hepatol 2015;62:1148–1155.
[17] Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis
progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a
systematic review and meta-analysis of paired-biopsy studies. Clin Gas-
troenterol Hepatol 2015;13:643–654.
[18] Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, et al.
Health-related quality of life in nonalcoholic fatty liver disease associates
with hepatic inflammation. Clin Gastroenterol Hepatol 2019;17:2085–
2092.
[19] Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications:
evidence based treatment. World J Gastroenterol 2014;20:5442–5460.
[20] Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK,
Dierkhising RA. Frequency and outcomes of liver transplantation for
nonalcoholic steatohepatitis in the United States. Gastroenterology
2011;141:1249–1253.
[21] Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic
fatty liver disease and nonalcoholic steatohepatitis in the United States
and the rest of the world. Clin Liver Dis 2016;20:205–214.
[22] Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM,
et al. Nonalcoholic steatohepatitis is the second leading etiology of liver
disease among adults awaiting liver transplantation in the United States.
Gastroenterology 2015;148:547–555.
[23] Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y,
et al. The economic and clinical burden of nonalcoholic fatty liverJHEP Reports 2020disease in the United States and Europe. Hepatology 2016;64:1577–
1586.
[24] European Association for the Study of the Liver (EASL); European Asso-
ciation for the Study of Diabetes (EASD); European Association for the
Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for
the management of non-alcoholic fatty liver disease. J Hepatol
2016;64:1388–1402.
[25] EuroQol Group. EuroQol–a new facility for the measurement of health-
related quality of life. Health Policy 1990;16:199–208.
[26] Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol
Hepatol 2014;20:327–337.
[27] Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of ran-
domized trials for the treatment of nonalcoholic fatty liver disease.
Hepatology 2010;52:79–104.
[28] Diabetes Prevention Program Research Group. Reduction in the incidence
of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med
2002;346:393–403.
[29] Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL,
et al. Metformin for diabetes prevention: insights gained from the dia-
betes prevention program/diabetes prevention program outcomes study.
Diabetologia 2017;60:1601–1611.
[30] Younossi ZM, Henry L. Economic and quality-of-life implications of
non-alcoholic fatty liver disease. Pharmacoeconomics 2015;33:1245–1253.
[31] Ghamar Chehreh ME, Vahedi M, Pourhoseingholi MA, Ashtari S,
Khedmat H, Amin M, et al. Estimation of diagnosis and treatment costs of
non-alcoholic fatty liver disease: a two-year observation. Hepat Mon
2013;13:e7382.8vol. 2 j 100142
